 |
 |
 |
  |
|
 |
PRESS RELEASES |
 |
|
|
= Add Release to Briefcase |
| All Releases |
 |
Savient Pharmaceuticals Reports Second Quarter 2010 Financial Results
08-03-10
|
70.5 KB
|
| |
EAST BRUNSWICK, N.J., Aug 03, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared wi...
|
|
 |
Savient Pharmaceuticals to Hold Second Quarter 2010 Results Conference Call on Wednesday, August 4, 2010
07-28-10
|
7.2 KB
|
| |
EAST BRUNSWICK, N.J., July 28, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the second quarter 2010 following the close of the market on Tuesday, August 3, 2010.
Paul Hamelin, President, and David Gionco, Group Vice President, Chief Fin...
|
|
 |
Savient Pharmaceuticals Provides Update on Corporate Strategy and Reports First Quarter 2010 Financial Results
05-05-10
|
19.2 KB
|
| |
EAST BRUNSWICK, N.J., May 5, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA(TM) by the U.S. Food and Drug Administration (FDA) (assuming KRYSTEXXA is approve...
|
|
 |
Savient Pharmaceuticals To Hold First Quarter 2010 Results
04-30-10
|
7.5 KB
|
| |
EAST BRUNSWICK, N.J., April 30, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the first quarter 2010 following the close of the market on Wednesday May 5, 2010.
Paul Hamelin, R.Ph., President and David Gionco, Group Vice President and Ch...
|
|
 |
Savient Announces KRYSTEXXA(TM) Resubmitted BLA Accepted for Review by the FDA
03-30-10
|
10.0 KB
|
| |
EAST BRUNSWICK, N.J., March 30, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase), a t...
|
|
 |
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
03-15-10
|
10.6 KB
|
| |
EAST BRUNSWICK, N.J., March 15, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventiona...
|
|
 |
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
02-25-10
|
22.0 KB
|
| |
EAST BRUNSWICK, N.J., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three months and year ended December 31, 2009, ending the quarter with $108.2 million in cash and short-term investments, an increase of $29.6 million from December 31, 2008. In October 2...
|
|
 |
Savient to Present at the Cowen and Company 30th Annual Health Care Conference
02-22-10
|
7.0 KB
|
| |
EAST BRUNSWICK, N.J., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at 1:00 p.m. Eastern Time. The conference is being held at The Bost...
|
|
 |
Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
02-08-10
|
7.6 KB
|
| |
EAST BRUNSWICK, N.J., Feb 08, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2009 following the close of the market on Thursday, February 25, 2010.
Paul Hamelin, President and David Gionco, Group Vice Pres...
|
|
 |
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
01-08-10
|
14.6 KB
|
| |
EAST BRUNSWICK, N.J., Jan 08, 2010 /PRNewswire via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy...
|
|
 |
Savient To Present at the 28th Annual JP Morgan Healthcare Conference
12-10-09
|
7.3 KB
|
| |
EAST BRUNSWICK, N.J., Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the JP Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m. Pacific Time. The conference is being held at Westin St. Franci...
|
|
 |
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
11-04-09
|
24.1 KB
|
| |
EAST BRUNSWICK, N.J., Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three and nine months ended September 30, 2009, ending the quarter with $67.5 million in cash and short-term investments, a reduction of $11.1 million from December 31, 2008. In ...
|
|
 |
Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009
10-28-09
|
7.5 KB
|
| |
EAST BRUNSWICK, N.J., Oct 28, 2009 /PRNewswire via COMTEX News Network/ -- EAST BRUNSWICK, N.J., Oct. 28 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2009 following the close of the market on Wednesday, November 4, 2009.
Paul Hamelin, President and David Gionco, ...
|
|
 |
Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
10-27-09
|
8.3 KB
|
| |
EAST BRUNSWICK, N.J., Oct 27, 2009 (GlobeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009.
The presentation is scheduled to begin on Tuesda...
|
|
 |
Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
10-15-09
|
7.8 KB
|
| |
EAST BRUNSWICK, N.J., Oct 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a resul...
|
|
 |
Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
10-08-09
|
7.9 KB
|
| |
EAST BRUNSWICK, N.J., Oct 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the pricing of an underwritten offering of 4,300,000 shares of its common stock at a price of $13.29 per share. After underwriting discounts and commissions and estimated offering expenses, Savient expec...
|
|
 |
Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
10-07-09
|
7.8 KB
|
| |
EAST BRUNSWICK, N.J., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today its intention to commence, subject to market and other conditions, an underwritten public offering of 4,000,000 shares of its common stock pursuant to an effective shelf registration statement on Form S-3...
|
|
 |
Savient Pharmaceuticals to Present At JMP Securities 4th Annual Healthcare Focus Conference
10-01-09
|
8.7 KB
|
| |
EAST BRUNSWICK, N.J., Oct 1, 2009 (GlobeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals, will be presenting at the upcoming JMP Securities 4th Annual Healthcare Focus Conference on October 6, 2009.
The presentation is scheduled to begin on T...
|
|
 |
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
09-16-09
|
13.7 KB
|
| |
EAST BRUNSWICK, N.J., Sept 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that on September 14, 2009, the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) received by Savient on July 31, 2009 rega...
|
|
 |
Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
09-08-09
|
11.2 KB
|
| |
EAST BRUNSWICK, N.J., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that five abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from Octob...
|
|
|
|
|
Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investor Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.
The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in the website are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding whether our KRYSTEXXA BLA resubmission, combined with the submissions made and planned by our third party contract manufacturer, fully addresses the deficiencies and observations raised and provides the additional materials requested in the Complete Response Letter that we received from the FDA on July 31, 2009, which were further clarified in our meeting with the FDA on September 14, 2009, the timing of FDA action with respect to the BLA resubmission, potential FDA marketing approval for KRYSTEXXA™, the efficacy and safety of KRYSTEXXA and the potential regulatory filings outside the United States and the potential for marketing approval in those jurisdictions are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 and Open Label Extension Study clinical data, our current understanding of the Complete Response Letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA, our third party contract manufacturer or require that we conduct additional clinical trials; our reliance on third parties to manufacture, market and distribute many of our products; our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this website to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.
|
  |
 |
Copyright © 2010 Savient Pharmaceuticals, Inc. All rights reserved. |
|
 |